Teladoc Sinks, Lilly Soars and ATTD
There are times we just have to gloat and today is one of those times as this morning Teladoc recorded a $6.6 billion impairment charge in the first quarter, reflecting the waning market value of its acquisition of chronic care company Livongo inked two years ago. As we predicted Teladoc vastly overvalued Livongo and this stupidity would eventually catch up with them. Well today it has as shares are now down almost 50%.
Back in the day when digital health was hotter than Georgia asphalt, we predicted there were only two possibilities for Livongo – either they . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.